ClinPGx Blog (Page 46)

Sign in Subscribe

More issues

PharmGKB welcomes Julia Barbarino to the team

We are pleased to welcome scientific curator Julia Barbarino to the PharmGKB team. Julia recently completed her master's in Medical Molecular Genetics from the University of Aberdeen, Scotland, where her research focused on epigenetic modifications of the apolipoprotein E gene and their role in human longevity. While undertaking

New VIP gene summary for CYP2E1

A new VIP summary is available for CYP2E1, a member of the cytochrome P450 family of drug metabolizing enzymes. CYP2E1 is constitutively expressed in the liver but makes up less than 1% of the total hepatic P450 isoforms [Article: 20100563]. It metabolizes relatively few prescription drugs (approximately 2%), however its

PharmGKB welcomes Ugur Hodoglugil to the team

We are pleased to welcome scientific curator Ugur Hodoglugil to the PharmGKB team. Previously, Ugur has worked as research scientist on identifying the genetic determinants of complex traits (lipid and other metabolic phenotypes) and population structure at Gladstone Institutes, University of California San Francisco where he analyzed genome-wide scans

New PGRN Featured Project and PI for the Month of November

The PGRN website is featuring a new project and investigator of the month from the PAT (Pharmacogenomics of Arrhythmia Therapy) group.For detailed information, please visit the PGRN website.

From Genomics & Informatics to Precision Medicine

Several PharmGKB curators plan to attend UCSF's Institute for Human Genetics 2012 Symposium on Monday 5th Nov, entitled "From Genomics and Informatics to Precision Medicine". Speakers include those from Genentech, Kaiser Permanente and prominent universities in the USA. We hope to see you there!

PharmGKB team celebrates Halloween

The PharmGKB team joined the Halloween celebrations this week - take a look at our pumpkin carving skills!

ASHG Annual Meeting 2012 (6th-10th Nov)

The PharmGKB curators will be attending the American Society of Human Genetics Annual Meeting in San Francisco next week and look forward to a week of interesting talks and posters. On Thursday 8th November (2:15-3:15pm) we will be presenting two posters - one focusing on the pharmacogenomic research

Defining our lists of PGx information

With the increasing implementation of pharmacogenomics knowledge we are often asked "What is the difference between the CPIC gene list, VIP list and the Clinical Annotations list on PharmGKB?" Here we clarify their contents: VIP genes (purple layer of the PharmGKB Knowledge Pyramid) This is a list of

New pathway: Vemurafenib Pathway, Pharmacodynamics

We have added a new pathway: Vemurafenib PD pathway to our pathway collections. Vemurafenib (marketed as ZELBORAF) is an oral BRAF inhibitor used to treat late-stage melanoma. It specifically targets the mutant BRAF protein (V600E isoform) that is found in approximately half of all cases of melanoma. Vemurafenib is

PharmGKB welcomes Daniel Klein to the team

We are pleased to welcome curator Daniel Klein to the PharmGKB team. Daniel recently graduated from the University of California, San Diego. His background is physics (specializing in astrophysics) with minors in biology, chemistry, and psychology. During his senior year at UCSD, Daniel worked as a part-time curator for